

# Predicting Anxiety and Depression Among Patients With COVID-19 in Concentrated Isolation at Medical Camps in Vietnam: A Descriptive Cross-Sectional Study

### OPEN ACCESS

#### Edited by:

Marco Grados, Johns Hopkins Medicine, United States

#### Reviewed by:

Wen-Jun Tu, Chinese Academy of Medical Sciences and Peking Union Medical College, China Jelena Vrublevska, Riga Stradiņš University, Latvia

#### \*Correspondence:

Le Van Truong bs.vantruong@gmail.com †These authors share first authorship

#### Specialty section:

This article was submitted to Anxiety and Stress Disorders, a section of the journal Frontiers in Psychiatry

Received: 27 November 2021 Accepted: 20 April 2022 Published: 31 May 2022

#### Citation:

Trang VTT, Huynh KLA, Truong HT, Nguyen HT, Hoang GT, Dao DQ, Van Vu U, Hassan Z, Nguyen MNH and Truong LV (2022) Predicting Anxiety and Depression Among Patients With COVID-19 in Concentrated Isolation at Medical Camps in Vietnam: A Descriptive Cross-Sectional Study. Front. Psychiatry 13:823586. doi: 10.3389/fpsyt.2022.823586 Vu Thi Thu Trang<sup>1†</sup>, Khoa Le Anh Huynh<sup>2†</sup>, Huyen Thi Truong<sup>3</sup>, Hue Thi Nguyen<sup>3</sup>, Giang Truong Hoang<sup>4</sup>, Dat Quang Dao<sup>5</sup>, Ut Van Vu<sup>3</sup>, Zair Hassan<sup>6</sup>, My Ngoc Ha Nguyen<sup>2</sup> and Le Van Truong<sup>3\*</sup>

<sup>1</sup> Acupuncture Department, National Hospital of Traditional Medicine, Hanoi, Vietnam, <sup>2</sup> Department of Biostatistics, School of Medicine, Virginia Commonwealth University, Richmond, VA, United States, <sup>3</sup> Traditional Medicine Hospital, Ministry of the Public Security, Hanoi, Vietnam, <sup>4</sup> U Buou Hospital, Bac Giang City, Vietnam, <sup>5</sup> Son Uyen General Hospital, Bac Giang City, Vietnam, <sup>6</sup> Lady Reading Hospital, Peshawar, Pakistan

**Introduction:** This study aims to assess the requirement for anxiety and depression treatment for patients with coronavirus disease 2019 (COVID-19) in medical camps in Bac Giang province, Vietnam. This information can help improve the government policy to reduce anxiety and depression in patients with COVID-19.

**Methods:** A total of patients with 427 COVID-19 participated in the survey conducted from 5 to 15 June 2021 in Bac Giang province. The survey included 17 questions about the general characteristics of the patients, 15 questions to assess common COVID-19 symptoms, the Patient Health Questionnaire-9 (PHQ-9), and General Anxiety Disorder-7 (GAD-7) scores, and four questions to assess hospital reviews, including facilities, food, medical staff, and living conditions. Logistics regression analyses were conducted to assess the association between COVID-19 symptoms and high anxiety and depression (HAD) status.

**Results:** A logistic regression analysis evaluated the risk factors in need of intervention. Our study showed that lower hospital review scores (odd ratio = 0.98; 95% confident interval = 0.97-0.99) were found to be a risk needing intervention. It was also identified that older patients (odd ratio = 1.1; 95% confident interval = 1.03-1.18), women (odd ratio = 1.31; 95% confident interval = 1.09-1.31), patients who were primary income earners in the family (odd ratio = 1.16; 95% confident interval = 1.06-1.21), and patients who had headaches (odd ratio = 1.17; 95% confident interval = 1.06-1.21), were risk factors for HAD status.

1

**Conclusion:** Our research shows that every 10-year age increase was associated with a 10% increase in the likelihood of HAD status. Study subjects being primary income earners were also associated with a 15% increased risk of having HAD status. This study showed that a decrease in family income due to COVID-19 caused an increase in high-level anxiety/depression status.

Keywords: depression, COVID-19, anxiety, multiple logistics regression, medical camps

# INTRODUCTION

On 1 December 2019, the first patient infected with severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) was reported in Wuhan, China, and was described with strange pneumonia (1, 2). While complex transmission mechanisms had often been mentioned for SARS-CoV-2, such as surface contact and fecal-oral or airborne transmission (3, 4), the main transmission would in fact be direct human-to-human (3, 4). Four months after the first infected patients, SARS-CoV-2 had spread globally and became a humanitarian disaster (5, 6).

Although the first COVID-19 death occurred on 22 January, 2020, in Wuhan, China, the Vietnamese government immediately took strong measures to control the situation. Early decisions included social distancing and the isolation of all infected and suspected cases. This allowed Vietnam to control the average daily number of infections to about 6.2 cases. Centralized isolation measures significantly reduced the spread of infection sources. Bac Giang province was under such control for more than 4 months. The fourth wave of COVID-19 at the end of April 2021, consisting of the Delta variant of the virus, caused an outbreak in Bac Giang province. According to a report, authorities were required to isolate 5,779 F0 patients who were inflected by COVID-19, and 43,469 F1 cases who were in close contact with infected patients for 14 days (7). With merely nine

hospitals in the province, only patients with severe symptoms were admitted. To meet the need for isolation, 326 medical camps were established (7), making use of sports halls, schools, factories, and so forth. However, these camps had inadequate facilities and limited living conditions. In addition, evidence showed that isolation were associated with psychological effects (8, 9). Our study was designed to assess the status of anxiety and depression in the medical camps in Bac Giang. Such an assessment could provide information regarding factors influencing the situation, which, in turn, could improve government policy to reduce depression and anxiety in patients with COVID-19.

# MATERIALS AND METHODS

### **Study Design and Participants**

This study with a cross-sectional descriptive study was conducted in medical camps in Bac Giang province from 5 to 15 June 2021. The study excluded participants in Bac Giang Province Hospital, patients under 18 years old, and patients who refuse to download the ZALO app. We randomly selected isolated patients and conducted an online survey through Google Forms. After that, we communicated with the patients through the ZALO app to track their symptoms.



#### TABLE 1 | Sociodemographic characteristics by anxiety and depression status.

	Low anxiety and depression $N = 253$	epression High anxiety or depression N = 174		P-value
Age (years)	26.2 (6.95)	30.0 (6.87)	27.7 (7.16)	< 0.00
Isolation time until survey (days)	19.8 (7.63)	20.9 (7.77)	20.3 (7.70)	0.144
Confirmed time until survey (days)	12.1 (4.59)	13.0 (5.68)	12.5 (5.07)	0.074
Gender	12.1 (4.03)	13.0 (3.00)	12.0 (0.07)	< 0.00
Male	105 (41.5%)	30 (17.2%)	135 (31.6%)	<0.00
Female	148 (58.5%)	144 (82.8%)	292 (68.4%)	
Jobs	140 (00.070)	144 (02.070)	232 (00.470)	0.164
Manual labor	217 (85.8%)	161 (92.5%)	378 (88.5%)	0.104
Office staff	4 (1.58%)	2 (1.15%)	6 (1.41%)	
Student	12 (4.74%)	2 (1.15%)	14 (3.28%)	
Farmer				
Others	6 (2.37%)	4 (2.30%)	10 (2.34%) 19 (4.45%)	
Marital status	14 (5.53%)	5 (2.87%)	19 (4.45%)	0.001
	100 (41 00/)	40 (04 70/)	140 (04 00()	0.001
Single	106 (41.9%)	43 (24.7%)	149 (34.9%)	
Married/Domestic partnership	139 (54.9%)	126 (72.4%)	265 (62.1%)	
Divorced/Widowed/Separated	8 (3.16%)	5 (2.87%)	13 (3.04%)	0.000
Number of relatives with COVID-19			000 (7 ( 70()	0.002
None	173 (68.4%)	133 (76.4%)	306 (71.7%)	
1 person	33 (13.0%)	17 (9.77%)	50 (11.7%)	
2 persons	17 (6.72%)	19 (10.9%)	36 (8.43%)	
3 persons	9 (3.56%)	4 (2.30%)	13 (3.04%)	
≥4 persons	21 (8.30%)	1 (0.57%)	22 (5.15%)	
Level of education				0.024
University/Master/PhD/Doctoral	6 (2.37%)	2 (1.15%)	8 (1.87%)	
College	9 (3.56%)	4 (2.30%)	13 (3.04%)	
Vocational training	7 (2.77%)	2 (1.15%)	9 (2.11%)	
High school	129 (51.0%)	78 (44.8%)	207 (48.5%)	
Secondary school	91 (36.0%)	66 (37.9%)	157 (36.8%)	
Primary school	9 (3.56%)	21 (12.1%)	30 (7.03%)	
No formal education	2 (0.79%)	1 (0.57%)	3 (0.70%)	
Main income earner in the family				< 0.00
No	89 (35.2%)	26 (14.9%)	115 (26.9%)	
Yes	164 (64.8%)	148 (85.1%)	312 (73.1%)	
Average income (USD)				0.146
<130	15 (5.93%)	8 (4.60%)	23 (5.39%)	
130–220	71 (28.1%)	69 (39.7%)	140 (32.8%)	
220–440	161 (63.6%)	93 (53.4%)	254 (59.5%)	
440–660	3 (1.19%)	3 (1.72%)	6 (1.41%)	
660–880	2 (0.79%)	1 (0.57%)	3 (0.70%)	
>880	1 (0.40%)	0 (0.00%)	1 (0.23%)	
Isolation status				0.067
Voluntary	253 (100%)	171 (98.3%)	424 (99.3%)	
Forced	0 (0.00%)	3 (1.72%)	3 (0.70%)	
The enneagram personality				0.924
The reformer	3 (1.19%)	1 (0.57%)	4 (0.94%)	
The individualist	4 (1.58%)	2 (1.15%)	6 (1.41%)	
The investigator	2 (0.79%)	1 (0.57%)	3 (0.70%)	
The challenger	42 (16.6%)	22 (12.6%)	64 (15.0%)	
The enthusiast	19 (7.51%)	18 (10.3%)	37 (8.67%)	
The peacemaker	119 (47.0%)	82 (47.1%)	201 (47.1%)	
The achiever	1 (0.40%)	1 (0.57%)	2 (0.47%)	
The helper	57 (22.5%)	44 (25.3%)	101 (23.7%)	
The loyalist	6 (2.37%)	3 (1.72%)	9 (2.11%)	

Frontiers in Psychiatry | www.frontiersin.org

#### Predicting Psychological for COVID-19 Patients

#### TABLE 1 | (Continued)

	Low anxiety and depression	High anxiety or depression	Total	P-value	
	N = 253	<i>N</i> = 174 <i>N</i> = 427			
Personality changes				<0.001	
Irritability	24 (9.49%)	62 (35.6%)	86 (20.1%)		
No change	211 (83.4%)	110 (63.2%)	321 (75.2%)		
More peaceful	18 (7.11%)	2 (1.15%)	20 (4.68%)		
Review of facilities	4.12 (0.80)	3.91 (0.89)	4.04 (0.85)	0.016	
Review of living conditions	3.96 (0.85)	3.82 (0.92)	3.90 (0.88)	0.125	
Review of food	4.29 (0.76)	4.06 (0.89)	4.20 (0.82)	0.005	
Review of medical staff	4.44 (0.72)	4.29 (0.82)	4.38 (0.77)	0.059	
Medical camp review (points)	16.8 (2.75)	16.1 (3.15)	16.5 (2.94)	0.015	
Worried				0.072	
Family is stigmatized	7 (2.77%)	2 (1.15%)	9 (2.11%)		
No one to take care of children	4 (1.58%)	7 (4.02%)	11 (2.58%)		
Family finances are not secure	30 (11.9%)	27 (15.5%)	57 (13.3%)		
Personal health	156 (61.7%)	115 (66.1%)	271 (63.5%)		
Family health	38 (15.0%)	18 (10.3%)	56 (13.1%)		
Others	18 (7.11%)	5 (2.87%)	23 (5.39%)		

# **Questionnaire Design**

The survey included 17 questions about the general characteristics of the patients, 15 questions to assess common symptoms, the Patient Health Questionnaire-9 (PHQ-9), and General Anxiety Disorder-7 (GAD-7) scores. Categories of depression symptoms were defined as low depression (PHQ-9 score 0-9) and high depression (PHQ-9 score  $\geq$  10) (10). Categories of anxiety symptoms were defined as low anxiety (GAD-7 score 0-9) and high anxiety (GAD-7 score  $\geq$  10) (11). The low anxiety and depression (LAD) group included patients with low anxiety or low depression. In contrast, the high anxiety and depression (HAD) group included patients with moderate and severe anxiety or moderate and severe depression (moderate or severe). Finally, the survey participants graded the medical camps based on four criteria: facilities, food, medical staff, and living conditions on a 5-level Likert scale (1: very poor; 5: very good).

### **Statistics Analysis**

The Shapiro-Wilk test was conducted to test the normal distribution hypothesis for continuous variables. Comparisons were made using a *t*-test for continuous variables with normal distribution, and the Mann-Whitney U test for continuous variables with non-normal distribution. Data were presented as the number of patients (percent) for categorical variables. The Chi-square test (if the expected value in cell > 5) and the Fisher exact test (if the expected value in cell < 5) were conducted for categorical variables to compare baseline characteristics between the study groups (intervention and non-intervention). The correlation between Patient Health Questionnaire-9 and General Anxiety Disorder-7 was determined. Univariate and multivariate logistics regressions were conducted to evaluate the odds ratio (OR) and 95% confidence interval (95% CI) of factors between the intervention group and the nonintervention group. All hypotheses were tested as two tails, with

a *p*-value < 0.05 considered statistically significant. Statistical analyses were performed using RStudio version 3.6.2.

### **Ethical Consideration**

The ethics committee approved all procedures of Traditional Medicine Hospital-Ministry of Public Security, Hanoi, Vietnam (No.664/QD-YHCT). Consent forms were attached to the survey questionnaire, and the patients only took the survey after accepting the terms of the study.

# RESULTS

A total of 427 patients with COVID-19 participated in this study, with a response rate of 64.2%. Men made up 31.6% of the participants, while women made up 68.4%. The mean participant age was 27.7 (standard deviation = 7.16). Moreover, 174 patients (40.7%) were identified as HAD. **Figure 1** shows a positive correlation between PHQ-9 and GAD-7 scores. Specifically, the proportion of patients with a GAD-7 score greater than or equal to 10 and a PHQ-9 score less than 10 is relatively low.

According to **Table 1**, the mean age of the subjects in the HAD group was 30 (6.87), which was statistically significantly higher than in the LAD group, whose mean age was 26.2 (6.95). In the HAD group, 82.8% of the patients were women, compared to the 58.5% in the LAD group. Furthermore, in the HAD group, 85.1% of patients were defined as primary workers in the family, which was significantly higher than in the LAD group (68.4%). According to the personality changes criterion, the HAD group had a significantly higher rate of irritability; 35.6% compared to the 9.49% of the LAD group. The LAD group evaluated facilities, food, living conditions, and medical staff higher than the HAD group. In particular, statistical significance was found between the two groups in facilities (p-value = 0.016) and food (p-value = 0.005).

Predicting Psychological f	for COVID-19 Patients
----------------------------	-----------------------

TABLE 2   Symptoms of coronavirus disease 2019 (COVID-19) by anxiety and
depression status.

Number of symptoms $5.21$ ( $3.44$ ) $7.95$ Body temperature $37.4$ ( $0.86$ ) $37.7$ Asymptomatic         Yes $23$ ( $9.09\%$ ) $1$ ( $0$ No $230$ ( $90.9\%$ ) $173$ ( $0.86$ ) $37.7$ Asymptomatic         Yes $230$ ( $90.9\%$ ) $173$ ( $0.86$ )           Fever symptom         No $230$ ( $90.9\%$ ) $173$ ( $0.86$ )           No $141$ ( $55.7\%$ ) $56$ ( $3$ Yes $112$ ( $44.3\%$ ) $118$ ( $0.60$ )           Cough         No $73$ ( $28.9\%$ ) $38$ ( $2.9\%$ )           No $73$ ( $28.9\%$ ) $38$ ( $2.9\%$ ) $38$ ( $2.9\%$ )           Yes $180$ ( $71.1\%$ ) $136$ ( $0.9\%$ ) $316$ ( $2.9\%$ )           Shortness of breath         No $188$ ( $74.3\%$ ) $81$ ( $4.6\%$ ) $31$ ( $0.9\%$ )           Yes $65$ ( $25.7\%$ ) $93$ ( $2.9\%$ ) $35$ ( $53.6\%$ ) $93$ ( $2.9\%$ )           Sore throat         No $142$ ( $56.1\%$ ) $14.0$ ( $0.9\%$ ) $10.0$ ( $142$ ( $56.1\%$ ) $11.0$ ( $1.9\%$ )           Headache         No $135$ ( $53.4\%$ ) $43$ ( $2.9\%$ ) $136$ ( $2.9\%$ )	High anxiety or depression	Total	P-value	
Body temperature       37.4 (0.86)       37.7         Asymptomatic       Yes       23 (9.09%)       1 (0)         No       230 (90.9%)       173 (9)         Fever symptom       112 (44.3%)       118 (0)         Cough       112 (44.3%)       118 (0)         No       73 (28.9%)       38 (2)         Yes       180 (71.1%)       136 (0)         Shortness of breath       110 (0)         No       73 (28.9%)       38 (2)         Yes       180 (71.1%)       136 (0)         Shortness of breath       110 (0)         No       142 (56.1%)       64 (2)         Yes       111 (43.9%)       110 (0)         Headache       110 (0)         No       142 (56.1%)       64 (2)         Yes       135 (53.4%)       143 (2)         Yes       135 (53.4%)       143 (2)         Yes       135 (53.4%)       43 (2)         Yes       135 (53.4%)       43 (2)         Yes       37 (14.6%)       66 (3)         Joint pain       112 (1)       112 (1)         No       168 (66.4%)       76 (4)         Yes       37 (14.6%)       68 (2)         Join	= 174	N = 427		
Asymptomatic         Yes       23 (9.09%)       1 (0)         No       230 (90.9%)       173 (s)         Fever symptom	(3.34)	6.33 (3.65)	< 0.001	
Yes23 $(9.09\%)$ 1 (0No230 $(90.9\%)$ 173 (2)Fever symptom112No141 $(55.7\%)$ 56 (3)Yes112 $(44.3\%)$ 118 (0)Cough138 (74.3\%)81 (4)No188 $(74.3\%)$ 81 (4)Yes65 $(25.7\%)$ 93 (5)Shortness of breath110 (0)No142 $(56.1\%)$ 64 (3)Yes111 $(43.9\%)$ 110 (0)Headache111 $(43.9\%)$ 110 (0)No135 $(53.4\%)$ 43 (2)Yes135 $(53.4\%)$ 43 (2)Yes118 $(46.6\%)$ 31 (1)Yes135 $(53.4\%)$ 43 (2)Yes135 $(53.4\%)$ 43 (2)Yes135 $(53.4\%)$ 43 (2)Yes136 $(66.4\%)$ 76 (4)Yes138 $(46.6\%)$ 76 (4)Yes168 $(66.4\%)$ 76 (4)Yes33 $(32.8\%)$ 86 (2)Joint painNo168 $(66.4\%)$ 76 (4)No170 $(67.2\%)$ 88 (5)Joint painNo145 $(57.3\%)$ 66 (3)No145 $(57.3\%)$ 66 (3)86 (2)DiarrheaNo145 $(57.3\%)$ 66 (3)No145 $(57.3\%)$ 66 (3)86 (2)Yes170 $(67.2\%)$ 186 (2)Yes170 $(67.2\%)$ 136 (2)Loss of smellNo145 $(57.3\%)$ 66 (3)No145 $(57.3\%)$ 66 (3)Yes170 $(67.2\%)$ 136 (2)Yes170 $(67.2\%)$	(0.93)	38.4 (15.9)	< 0.001	
No       230 (90.9%)       173 (0)         Fever symptom       141 (55.7%)       56 (3)         Yes       112 (44.3%)       118 (0)         Cough       112 (44.3%)       118 (0)         No       73 (28.9%)       38 (2)         Yes       180 (71.1%)       136 (0)         Shortness of breath       110 (0)         No       188 (74.3%)       81 (4)         Yes       65 (25.7%)       93 (5)         Sore throat       110 (0)         No       142 (56.1%)       64 (2)         Yes       111 (43.9%)       110 (0)         Headache       110 (0)       142 (56.1%)       64 (2)         No       142 (56.1%)       143 (0)         Muscle pain       110 (0)       144 (6.6%)       31 (1)         Yes       135 (53.4%)       43 (2)         Yes       135 (53.4%)       13 (2)         Yes       118 (46.6%)       13 (1)         Chest tightness       118 (46.6%)       13 (1)         No       168 (66.4%)       76 (4)         Yes       33 (32.8%)       86 (2)         Joint pain       112 (1)       112 (1)         No       170 (67.2%)			< 0.001	
Fever symptom         Fever symptom           No         141 (55.7%)         56 (3)           Yes         112 (44.3%)         118 (1)           Cough	.57%)	24 (5.62%)		
No $141 (55.7\%)$ $56 (3)$ Yes $112 (44.3\%)$ $118 (1)$ Cough	99.4%)	403 (94.4%)		
Yes       112 (44.3%)       118 (         Cough       73 (28.9%)       38 (2         Yes       180 (71.1%)       136 (         Shortness of breath       118       118 (         No       188 (74.3%)       81 (4         Yes       65 (25.7%)       93 (5         Sore throat       110 (         No       142 (56.1%)       64 (3         Yes       111 (43.9%)       110 (         Headache       111 (43.9%)       110 (         Headache       118 (46.6%)       31 (1         Yes       135 (53.4%)       43 (2         Yes       135 (53.4%)       43 (2         Yes       118 (46.6%)       131 (         Chest tightness       118 (46.6%)       131 (         No       168 (66.4%)       76 (4         Yes       85 (33.6%)       98 (5         Joint pain       No       168 (66.4%)       76 (4         Yes       37 (14.6%)       62 (3         Diarrhea       No       170 (67.2%)       88 (5         No       145 (57.3%)       66 (3         Yes       108 (42.7%)       108 (4         Loss of taste       No       145 (57.3%)			<0.001	
Cough       73 (28.9%)       38 (2         Yes       180 (71.1%)       136 (         Shortness of breath       138 (74.3%)       81 (4         Yes       65 (25.7%)       93 (5         Sore throat       142 (56.1%)       64 (3         Yes       111 (43.9%)       110 (         Headache       111 (43.9%)       110 (         Headache       118 (46.6%)       31 (1         Yes       135 (53.4%)       143 (         Muscle pain       135 (53.4%)       43 (2         Yes       118 (46.6%)       131 (         Chest tightness       118 (46.6%)       131 (         No       135 (53.4%)       43 (2         Yes       118 (46.6%)       131 (         Chest tightness       118 (46.6%)       131 (         No       135 (53.4%)       43 (2         Yes       37 (14.6%)       62 (3         Joint pain       No       168 (66.4%)       76 (4         Yes       37 (14.6%)       62 (3         Diarthea       No       170 (67.2%)       88 (5         Yes       108 (42.7%)       108 (4         Yes       108 (42.7%)       108 (4         Yes	32.2%)	197 (46.1%)		
No         73 (28.9%)         38 (2           Yes         180 (71.1%)         136 (7           Shortness of breath         138 (74.3%)         81 (4           Yes         65 (25.7%)         93 (5           Sore throat         111 (43.9%)         110 (7           Headache         111 (43.9%)         110 (7           Headache         118 (46.6%)         31 (1           Yes         135 (53.4%)         43 (2           Yes         135 (53.4%)         43 (2           Yes         135 (53.4%)         43 (2           Yes         138 (46.6%)         76 (4           Yes         138 (66.4%)         76 (4           Yes         138 (66.4%)         76 (4           Yes         85 (33.6%)         98 (5           Joint pain         Vo         168 (66.4%)         76 (4           Yes         37 (14.6%)         62 (25           Joint pain         Vo         216 (85.4%)         112 (10           Yes         37 (14.6%)         62 (25           Diarthea         Vo         170 (67.2%)         88 (5           Yes         33 (32.8%)         86 (4           Loss of taste         Vo         108 (1 <td>67.8%)</td> <td>230 (53.9%)</td> <td></td>	67.8%)	230 (53.9%)		
No $73 (28.9\%)$ $38 (2)$ Yes $180 (71.1\%)$ $136 (7)$ Shortness of breath $138 (74.3\%)$ $81 (4)$ Yes $65 (25.7\%)$ $93 (5)$ Sore throat $142 (56.1\%)$ $64 (3)$ Yes $111 (43.9\%)$ $110 (7)$ Headache $118 (46.6\%)$ $31 (1)$ Yes $135 (53.4\%)$ $143 (7)$ Muscle pain $135 (53.4\%)$ $43 (2)$ Yes $118 (46.6\%)$ $31 (1)$ Yes $135 (53.4\%)$ $43 (2)$ Yes $135 (53.4\%)$ $43 (2)$ Yes $118 (46.6\%)$ $131 (1)$ Chest tightness $112 (1)$ No $135 (53.4\%)$ $43 (2)$ Yes $31 (1) (1)$ $112 (1)$ Yes $31 (1) (1) (1) (1) (1) (1) (1) (1) (1) (1$	,	,	0.131	
Yes       180 (71.1%)       136 (         Shortness of breath       188 (74.3%)       81 (4         No       188 (74.3%)       81 (4         Yes       65 (25.7%)       93 (5         Sore throat       93 (5         No       142 (56.1%)       64 (3         Yes       111 (43.9%)       110 (1         Headache       118 (46.6%)       31 (1         Yes       135 (53.4%)       43 (2         Yes       135 (53.4%)       43 (2         Yes       138 (46.6%)       143 (1         Muscle pain       100       118 (46.6%)       131 (1         Yes       135 (53.4%)       43 (2       Yes       136 (1         Yes       138 (66.4%)       76 (4       Yes       137 (1       136 (1         Chest tightness       118 (46.6%)       131 (1       131	21.8%)	111 (26.0%)		
Shortness of breath       81 (4         No       188 (74.3%)       81 (4         (res       65 (25.7%)       93 (5         Sore throat       93       93         No       142 (56.1%)       64 (3         rées       111 (43.9%)       110 (0         Headache       93       111 (43.9%)       110 (0         Headache       93       113 (10 (0       114 (46.6%))       31 (1         Yes       135 (53.4%)       43 (2       113 (0       113 (0         Muscle pain       93       135 (53.4%)       43 (2       113 (0         Muscle pain       93       113 (10 (0	78.2%)	316 (74.0%)		
No $188 (74.3\%)$ $81 (4)$ Yes $65 (25.7\%)$ $93 (5)$ Sore throat $142 (56.1\%)$ $64 (3)$ Yes $111 (43.9\%)$ $110 (1)$ Headache $111 (43.9\%)$ $110 (1)$ Yes $135 (53.4\%)$ $143 (1)$ Yuscle pain $118 (46.6\%)$ $31 (1)$ Yes $135 (53.4\%)$ $43 (2)$ Yes $118 (46.6\%)$ $131 (1)$ Chest tightness $118 (46.6\%)$ $131 (1)$ Yo $168 (66.4\%)$ $76 (4)$ Yes $85 (33.6\%)$ $98 (5)$ Joint pain $112 (1)$ No $168 (66.4\%)$ $76 (4)$ Yes $37 (14.6\%)$ $62 (3)$ Diarrhea $112 (1)$ No $170 (67.2\%)$ $88 (5)$ Yes $33 (32.8\%)$ $66 (3)$ Yes $135 (57.3\%)$ $66 (3)$ Yes $108 (42.7\%)$ $108 (1)$ Loss of taste $108 (42.7\%)$ $108 (1)$ No $145 (57.3\%)$ $66 (3)$ Yes $108 (42.7\%)$ $108 (1)$ Loss of smell $108 (42.7\%)$ $136 (7)$ No $219 (90.5\%)$ $138 (7)$ Yes $229 (90.5\%)$ $138 (7)$ Yes $24 (9.49\%)$ $36 (2)$ Loss of ability to speak $108 (1)$ No $246 (97.2\%)$ $156 (7)$ Yes $7 (2.77\%)$ $18 (1)$	10.270)	010 (7 1.070)	<0.001	
Yes $65 (25.7\%)$ $93 (5)$ Sore throat $142 (56.1\%)$ $64 (3)$ No $142 (56.1\%)$ $64 (3)$ Yes $111 (43.9\%)$ $110 (1)$ Headache $111 (43.9\%)$ $110 (1)$ No $118 (46.6\%)$ $31 (1)$ Yes $135 (53.4\%)$ $43 (2)$ Muscle pain $118 (46.6\%)$ $113 (1)$ No $135 (53.4\%)$ $43 (2)$ Yes $135 (53.4\%)$ $43 (2)$ Yes $135 (53.4\%)$ $43 (2)$ Yes $118 (46.6\%)$ $131 (1)$ Chest tightness $118 (46.6\%)$ $131 (1)$ No $168 (66.4\%)$ $76 (4)$ Yes $85 (33.6\%)$ $98 (5)$ Joint pain $112 (1)$ No $216 (85.4\%)$ $112 (1)$ Yes $37 (14.6\%)$ $62 (3)$ Diarrhea $115 (57.3\%)$ $66 (3)$ No $145 (57.3\%)$ $66 (3)$ Yes $108 (42.7\%)$ $108 (1)$ Loss of taste $108 (42.7\%)$ $108 (1)$ No $81 (32.0\%)$ $38 (2)$ Yes $172 (68.0\%)$ $136 (1)$ Ko $229 (90.5\%)$ $138 (1)$ Yes $24 (9.49\%)$ $36 (2)$ Loss of ability to speak $100 (2) (2,7\%)$ $136 (1)$ No $246 (97.2\%)$ $156 (1)$ Yes $7 (2.77\%)$ $18 (1)$	16 6%)	260 (62 0%)	<0.001	
Sore throat       142 (56.1%)       64 (3)         No       142 (56.1%)       64 (3)         Yes       111 (43.9%)       110 (1)         Headache $111 (43.9\%)$ 110 (1)         Yes       135 (53.4%)       133 (1)         Yes       135 (53.4%)       143 (2)         Muscle pain $118 (46.6\%)$ 131 (1)         No       135 (53.4%)       43 (2)         Yes       118 (46.6%)       131 (1)         Chest tightness $118 (46.6\%)$ 131 (1)         No       168 (66.4%)       76 (4)         Yes       85 (33.6%)       98 (5)         Joint pain $112 (1)$ $112 (1)$ No       216 (85.4%)       112 (1)         Yes       37 (14.6%)       62 (3)         Diarrhea $112 (1)$ $112 (1)$ No       170 (67.2%)       88 (5)         Yes       33 (32.8%)       86 (4)         Loss of taste $100 (1)$ $100 (1)$ No       145 (57.3%)       66 (3)         Yes       108 (42.7%)       108 (1)         Loss of smell $100 (1)$ $100 (1)$ No       214 (32	,	269 (63.0%)		
No         142 (56.1%)         64 (3)           Yes         111 (43.9%)         110 (0)           Headache         111 (43.9%)         110 (0)           No         118 (46.6%)         31 (1)           Yes         135 (53.4%)         143 (2)           Muscle pain         118 (46.6%)         143 (2)           No         135 (53.4%)         43 (2)           Yes         118 (46.6%)         131 (1)           Chest tightness         118 (46.6%)         131 (1)           Chest tightness         118 (46.6%)         131 (1)           Chest tightness         112 (1)         112 (1)           Yes         85 (33.6%)         98 (5)           Joint pain         No         216 (85.4%)         112 (1)           Yes         37 (14.6%)         62 (3)           Diarrhea         No         170 (67.2%)         88 (6)           Loss of taste         No         145 (57.3%)         66 (3)           Yes         108 (42.7%)         108 (4)           Loss of smell         No         145 (57.3%)         66 (3)           Yes         172 (68.0%)         136 (1)           Yes         172 (68.0%)         136 (2) <td< td=""><td>JJ.4 70)</td><td>158 (37.0%)</td><td>-0.004</td></td<>	JJ.4 70)	158 (37.0%)	-0.004	
Yes       111 (43.9%)       110 (         Headache       118 (46.6%)       31 (1         No       118 (46.6%)       31 (1         Yes       135 (53.4%)       143 (         Muscle pain       118 (46.6%)       31 (1         No       135 (53.4%)       143 (         Muscle pain       118 (46.6%)       131 (1         No       135 (53.4%)       43 (2         Yes       118 (46.6%)       131 (1         Chest tightness       118 (46.6%)       131 (1         No       168 (66.4%)       76 (4         Yes       85 (33.6%)       98 (5         Joint pain       No       168 (65.4%)       112 (1         No       216 (85.4%)       112 (1         Yes       37 (14.6%)       62 (3         Diarrhea       No       170 (67.2%)       88 (5         Yes       83 (32.8%)       86 (4         Loss of taste       No       145 (57.3%)       66 (3         Yes       108 (42.7%)       108 (4         Loss of smell       No       145 (57.3%)       66 (2         Yes       172 (68.0%)       136 (7         Yes       129 (90.5%)       138 (7      <		000 (40 00)	<0.001	
Headache       31 (1         No       118 (46.6%)       31 (1         Yes       135 (53.4%)       143 (2         Muscle pain       35 (53.4%)       43 (2         Yes       118 (46.6%)       131 (1         No       135 (53.4%)       43 (2         Yes       118 (46.6%)       131 (1         Chest tightness       118 (46.6%)       131 (1         No       135 (53.4%)       43 (2         Yes       118 (46.6%)       131 (1         Chest tightness       118 (46.6%)       131 (1         No       168 (66.4%)       76 (4         Yes       85 (33.6%)       98 (5         Joint pain       No       216 (85.4%)       112 (1         Yes       37 (14.6%)       62 (3         Diarrhea       No       170 (67.2%)       88 (5         Yes       83 (32.8%)       86 (4         Loss of taste       No       145 (57.3%)       66 (3         Yes       108 (42.7%)       108 (4         Loss of smell       No       145 (57.3%)       66 (3         Yes       172 (68.0%)       136 (7         Ko       229 (90.5%)       138 (7         Yes	,	206 (48.2%)		
No       118 (46.6%)       31 (1         Yes       135 (53.4%)       143 (2         Muscle pain	63.2%)	221 (51.8%)		
Yes       135 (53.4%)       143 (         Muscle pain       135 (53.4%)       43 (2         Yes       118 (46.6%)       131 (         Chest tightness       118 (46.6%)       131 (         No       168 (66.4%)       76 (4         Yes       85 (33.6%)       98 (5         Joint pain       112 (r         No       216 (85.4%)       112 (r         Yes       37 (14.6%)       62 (3         Diarrhea       No       170 (67.2%)       88 (5         Yes       83 (32.8%)       86 (4         Loss of taste       No       145 (57.3%)       66 (3         Yes       108 (42.7%)       108 (r         Loss of smell       No       81 (32.0%)       38 (2         No       81 (32.0%)       38 (2       Yes       126 (2         Sys       172 (68.0%)       136 (7       Red eyes       136 (2         No       229 (90.5%)       138 (7       Yes       24 (9.49%)       36 (2         Loss of ability to speak       No       246 (97.2%)       156 (7         Yes       7 (2.77%)       18 (1       Yes       156 (7			<0.001	
Muscle pain       135 (53.4%)       43 (2         Yes       118 (46.6%)       131 (         Chest tightness       118 (46.6%)       131 (         No       168 (66.4%)       76 (4         Yes       85 (33.6%)       98 (5         Joint pain       112 (r         No       216 (85.4%)       112 (r         Yes       37 (14.6%)       62 (3         Diarthea       112 (r         No       170 (67.2%)       88 (5         Yes       83 (32.8%)       86 (4         Loss of taste       108 (42.7%)       108 (r         No       145 (57.3%)       66 (3         Yes       108 (42.7%)       108 (r         Loss of smell       108 (42.7%)       136 (r         No       81 (32.0%)       38 (2         Yes       172 (68.0%)       136 (r         Loss of smell       108 (r       138 (r         No       229 (90.5%)       138 (r         Yes       24 (9.49%)       36 (2         Loss of ability to speak       108 (r         No       246 (97.2%)       156 (r         Yes       7 (2.77%)       18 (r	17.8%)	149 (34.9%)		
No       135 (53.4%)       43 (2         Yes       118 (46.6%)       131 (         Chest tightness       1       1         No       168 (66.4%)       76 (4         Yes       85 (33.6%)       98 (5         Joint pain       1       1         No       216 (85.4%)       112 (1         Yes       37 (14.6%)       62 (3         Diarrhea       1       1         No       170 (67.2%)       88 (5         Yes       83 (32.8%)       86 (4         Loss of taste       1       1         No       145 (57.3%)       66 (3         Yes       108 (42.7%)       108 (1         Loss of smell       1       1         No       145 (57.3%)       66 (3         Yes       172 (68.0%)       136 (1         Loss of smell       1       1         No       229 (90.5%)       138 (1         Yes       24 (9.49%)       36 (2         Loss of ability to speak       1       1         No       246 (97.2%)       156 (1         Yes       7 (2.77%)       18 (1	82.2%)	278 (65.1%)		
Yes       118 (46.6%)       131 (         Chest tightness       118 (46.6%)       76 (4         Yes       85 (33.6%)       98 (5         Joint pain       112 (r         No       216 (85.4%)       112 (r         Yes       37 (14.6%)       62 (3         Diarrhea       112 (r         No       170 (67.2%)       88 (5         Yes       83 (32.8%)       86 (4         Loss of taste       108 (42.7%)       108 (r         No       145 (57.3%)       66 (3         Yes       108 (42.7%)       108 (r         Loss of smell       108 (42.7%)       108 (r         No       145 (57.3%)       66 (3         Yes       108 (42.7%)       108 (r         Loss of smell       108 (42.7%)       136 (r         No       24 (9.0%)       36 (2         Yes       172 (68.0%)       136 (r         Yes       24 (9.49%)       36 (2         Loss of ability to speak       108 (r         No       246 (97.2%)       156 (r         Yes       7 (2.77%)       18 (r			< 0.001	
Chest tightness         76 (4           Yes         85 (33.6%)         98 (5)           Joint pain         98 (5)           No         216 (85.4%)         112 (1)           Yes         37 (14.6%)         62 (3)           Diarrhea         98         60           No         170 (67.2%)         88 (5)           Yes         83 (32.8%)         86 (4)           Loss of taste         98         108 (42.7%)           No         145 (57.3%)         66 (3)           Yes         108 (42.7%)         108 (4)           Loss of smell         98         108 (42.7%)           No         145 (57.3%)         66 (3)           Yes         172 (68.0%)         136 (7)           Yes         172 (68.0%)         136 (7)           Yes         24 (9.49%)         36 (2)           Loss of ability to speak         100 (2)         100 (2)           Yes         24 (9.49%)         36 (2)           Loss of ability to speak         103 (2)         103 (2)	24.7%)	178 (41.7%)		
No       168 (66.4%)       76 (4         Yes       85 (33.6%)       98 (5         Joint pain       98       98         No       216 (85.4%)       112 (1         Yes       37 (14.6%)       62 (3         Diarrhea       98       66         No       170 (67.2%)       88 (5         Yes       83 (32.8%)       86 (4         Loss of taste       98       98         No       145 (57.3%)       66 (3         Yes       108 (42.7%)       108 (4         Loss of smell       98       98         No       81 (32.0%)       38 (2         Yes       172 (68.0%)       136 (1         Red eyes       229 (90.5%)       138 (1         No       229 (90.5%)       138 (1         Yes       24 (9.49%)       36 (2         Loss of ability to speak       108         No       246 (97.2%)       156 (1         Yes       7 (2.77%)       18 (1	75.3%)	249 (58.3%)		
Yes       85 (33.6%)       98 (5)         Joint pain       98 (5)         No       216 (85.4%)       112 (1)         Yes       37 (14.6%)       62 (3)         Diarrhea       98       60         No       170 (67.2%)       88 (5)         Yes       83 (32.8%)       86 (4)         Loss of taste       98         No       145 (57.3%)       66 (3)         Yes       108 (42.7%)       108 (4)         Loss of smell       108       108 (42.7%)         No       145 (57.3%)       66 (3)         Yes       108 (42.7%)       108 (4)         Loss of smell       108 (42.7%)       108 (4)         No       81 (32.0%)       38 (2)         Yes       172 (68.0%)       136 (7)         Red eyes       108       112 (1)         No       229 (90.5%)       138 (7)         Loss of ability to speak       108       1136 (7)         Loss of ability to speak       108       108         No       246 (97.2%)       156 (7)         Yes       7 (2.77%)       18 (1)			< 0.001	
Joint pain         216 (85.4%)         112 (r           No         216 (85.4%)         112 (r           Yes         37 (14.6%)         62 (s           Diarrhea         5           No         170 (67.2%)         88 (s           Yes         83 (32.8%)         86 (a           Loss of taste         5         66 (s           Yes         108 (42.7%)         108 (b           Loss of smell         5         108 (42.7%)           No         145 (57.3%)         66 (s           Yes         108 (42.7%)         108 (b           Loss of smell         5         108 (42.7%)           No         81 (32.0%)         38 (z           Yes         172 (68.0%)         136 (c           Red eyes         7         138 (c           No         229 (90.5%)         138 (c           Loss of ability to speak         5           No         246 (97.2%)         156 (c           Yes         7 (2.77%)         18 (t	13.7%)	244 (57.1%)		
No       216 (85.4%)       112 (r         Yes       37 (14.6%)       62 (3         Diarrhea       9         No       170 (67.2%)       88 (5         Yes       83 (32.8%)       86 (4         Loss of taste       9         No       145 (57.3%)       66 (3         Yes       108 (42.7%)       108 (6         Loss of smell       9       108 (42.7%)         No       81 (32.0%)       38 (2         Yes       172 (68.0%)       136 (7         Red eyes       12       9         No       229 (90.5%)       138 (7         Vo       229 (90.5%)       138 (7         Kes       24 (9.49%)       36 (2         Loss of ability to speak       108         No       246 (97.2%)       156 (7         Yes       7 (2.77%)       18 (1	56.3%)	183 (42.9%)		
Yes       37 (14.6%)       62 (3)         Diarrhea       70 (67.2%)       88 (5)         Yes       83 (32.8%)       86 (4)         Loss of taste       8       8         No       145 (57.3%)       66 (3)         Yes       108 (42.7%)       108 (4)         Loss of smell       108 (42.7%)       108 (4)         No       81 (32.0%)       38 (2)         Yes       172 (68.0%)       136 (1)         Red eyes       108       138 (2)         No       229 (90.5%)       138 (2)         Yes       24 (9.49%)       36 (2)         Loss of ability to speak       100       100 (2)         No       246 (97.2%)       156 (1)         Yes       7 (2.77%)       18 (1)			< 0.001	
Diarrhea         No         170 (67.2%)         88 (5           Yes         83 (32.8%)         86 (4           Loss of taste         108 (42.7%)         66 (3           Yes         108 (42.7%)         108 (4           Loss of smell         108 (42.7%)         108 (4           No         81 (32.0%)         38 (2           Yes         172 (68.0%)         136 (1           Red eyes         108         108 (1           No         229 (90.5%)         138 (1           Yes         24 (9.49%)         36 (2           Loss of ability to speak         100         100 (1           No         246 (97.2%)         156 (1           Yes         7 (2.77%)         18 (1	64.4%)	328 (76.8%)		
No         170 (67.2%)         88 (5           Yes         83 (32.8%)         86 (4           Loss of taste         1         1           No         145 (57.3%)         66 (3           Yes         108 (42.7%)         108 (4           Loss of smell         1         1           No         81 (32.0%)         38 (2           Yes         172 (68.0%)         136 (1           Red eyes         1         1           No         229 (90.5%)         138 (1           Yes         24 (9.49%)         36 (2           Loss of ability to speak         1         1           No         246 (97.2%)         156 (1           Yes         7 (2.77%)         18 (1	35.6%)	99 (23.2%)		
No         170 (67.2%)         88 (5           Yes         83 (32.8%)         86 (4           Loss of taste         1         1           No         145 (57.3%)         66 (3           Yes         108 (42.7%)         108 (4           Loss of smell         1         1           No         81 (32.0%)         38 (2           Yes         172 (68.0%)         136 (1           Red eyes         1         1           No         229 (90.5%)         138 (1           Yes         24 (9.49%)         36 (2           Loss of ability to speak         1         1           No         246 (97.2%)         156 (1           Yes         7 (2.77%)         18 (1	,	, ,	0.001	
Yes         83 (32.8%)         86 (4           Loss of taste	50.6%)	258 (60.4%)		
Loss of taste         145 (57.3%)         66 (3)           Yes         108 (42.7%)         108 (6)           Loss of smell         108 (42.7%)         108 (6)           No         81 (32.0%)         38 (2)           Yes         172 (68.0%)         136 (7)           Red eyes         229 (90.5%)         138 (7)           Yes         24 (9.49%)         36 (2)           Loss of ability to speak         100         156 (7)           Yes         7 (2.77%)         18 (1)	19.4%)	169 (39.6%)		
No         145 (57.3%)         66 (3           Yes         108 (42.7%)         108 (0           Loss of smell         108         108 (42.7%)           No         81 (32.0%)         38 (2           Yes         172 (68.0%)         136 (7           Red eyes         229 (90.5%)         138 (7           No         229 (90.5%)         138 (7           Yes         24 (9.49%)         36 (2           Loss of ability to speak         108           No         246 (97.2%)         156 (7           Yes         7 (2.77%)         18 (1			<0.001	
Yes     108 (42.7%)     108 (       Loss of smell     108 (       No     81 (32.0%)     38 (2       Yes     172 (68.0%)     136 (       Red eyes     108 (     108 (       No     229 (90.5%)     138 (       Yes     24 (9.49%)     36 (2       Loss of ability to speak     108 (       No     246 (97.2%)     156 (       Yes     7 (2.77%)     18 (1	87.0%)	211 (49.4%)	<0.001	
Loss of smell         81 (32.0%)         38 (2           Yes         172 (68.0%)         136 (           Red eyes         1         1           No         229 (90.5%)         138 (           Yes         24 (9.49%)         36 (2           Loss of ability to speak         1         1           No         246 (97.2%)         1         1           Yes         7 (2.77%)         18 (1	,	216 (50.6%)		
No         81 (32.0%)         38 (2           Yes         172 (68.0%)         136 (           Red eyes         1         1           No         229 (90.5%)         138 (           Yes         24 (9.49%)         36 (2           Loss of ability to speak         1           No         246 (97.2%)         156 (2           Yes         7 (2.77%)         18 (1	02.170)	210 (30.070)	0.000	
Yes     172 (68.0%)     136 (       Red eyes     172 (68.0%)     138 (       No     229 (90.5%)     138 (       Yes     24 (9.49%)     36 (2       Loss of ability to speak     100       No     246 (97.2%)     156 (       Yes     7 (2.77%)     18 (1		110 (07 00()	0.028	
Red eyes         229 (90.5%)         138 (           Yes         24 (9.49%)         36 (2           Loss of ability to speak         4           No         246 (97.2%)         156 (2           Yes         7 (2.77%)         18 (1	,	119 (27.9%)		
No         229 (90.5%)         138 (           Yes         24 (9.49%)         36 (2           Loss of ability to speak             No         246 (97.2%)         156 (           Yes         7 (2.77%)         18 (1	78.2%)	308 (72.1%)		
Yes         24 (9.49%)         36 (2           Loss of ability to speak         Xo         246 (97.2%)         156 (2           Yes         7 (2.77%)         18 (1			0.002	
Loss of ability to speak           No         246 (97.2%)         156 (r           Yes         7 (2.77%)         18 (1	79.3%)	367 (85.9%)		
No 246 (97.2%) 156 ( Yes 7 (2.77%) 18 (1	20.7%)	60 (14.1%)		
Yes 7 (2.77%) 18 (1			0.002	
	89.7%)	402 (94.1%)		
Rash	10.3%)	25 (5.85%)		
luon			0.016	
No 220 (87.0%) 135 (	77.6%)	355 (83.1%)		
Yes 33 (13.0%) 39 (2	22.4%)	72 (16.9%)		
Nausea/vomiting			<0.001	
•	59.8%)	309 (72.4%)		
	10.2%)	118 (27.6%)		

The HAD group had a significantly higher rate of symptoms than the LAD group, except for cough symptoms. According to **Table 2**, asymptomatic patients in the LAD group were 9.09%, approximately 16 times higher than in the HAD group. However, the difference between the two groups was not statistically significant in terms of cough symptoms (p = 0.131).

As shown in Table 3, HAD status was significantly higher among older patients, women, main income earners, and those suffering from shortness of breath, headaches, joint pain, and loss of speaking ability. Moreover, patients with loss of speaking ability have higher odd ratios of needing interventions than patients without this loss (OR = 1.39; 95% CI = 1.15-1.70). Besides these factors, hospitals with higher review scores had fewer patients in the HAD group (OR = 0.98; 95% CI = 0.96-1). According to the results of multiple binary logistic regression analysis evaluating the risk factors in need of intervention, lower hospital review scores (OR = 0.98; 95% CI = 0.97-0.99) were found to be a risk for needing intervention, while older patients (OR = 1.1; 95% CI = 1.03-1.18), women (OR = 1.31; 95% CI = 1.09-1.31), patients who were main income earners (OR = 1.15; 95% CI = 1.03 - 1.28), patients who had headaches (OR = 1.16; 95% CI = 1.06-1.21), and patients who had joint pain (OR = 1.17; 95% CI = 1.06-1.3) were identified as risk factors for HAD status.

### DISCUSSION

In the face of complicated developments of the COVID-19 epidemic in Vietnam, the government has taken an uncompromising approach to the centralized isolation of all confirmed cases. The measure has shown apparent effectiveness in controlling the COVID-19 outbreak. However, our study showed that the isolation process significantly impacted mental health. Symptoms of COVID-19 were positively correlated with depression and anxiety. Our study showed that age, confirmed cases until the survey, gender, being primary income earners, shortness of breath, headaches, joint pain, and loss of speaking ability were significantly associated with the likelihood of having HAD status. Furthermore, the medical camp review was significantly associated with reduction in LAD status. Our study points to the necessity of depression and anxiety treatment, such as psychological consultations, as well as the establishment of a policy to financially support low-income patients with COVID-19.

A previous study from Kong et al. (12) showed that the PHQ-9 and GAD-7 scales increase with age for COVID-19 patients. Our findings indicate that every 10-year increase in age was associated with a 10% increase in the likelihood of HAD status. The 1-week increase after the confirmation of COVID-19 was associated with a 4% increased likelihood of having HAD status. These results were similar to Yanyu Hu's study, which showed that the duration of COVID-19 was associated with a statistically significant increase in GAD-7 and PHQ-9 scores (13). Our results also showed that being female was associated with a 20% increased likelihood of having HAD status. This is similar to a previous study showing that women

Variables	Univariate analysis		Multivariable analysis	
	OR (95% CI)	P-value	OR (95% CI)	P-value
Age (10 years)	1.20 (1.12–1.28)	<0.001	1.10 (1.03–1.18)	0.006
Confirmed time until survey (weeks)	1.06 (1.00–1.13)	0.063	1.04 (0.99–1.11)	0.137
Hospital review (points)	0.98 (0.96-1.00)	0.013	0.98 (0.97-0.99)	0.007
Gender				
Male	Reference		Reference	
Female	1.31 (1.19–1.44)	<0.001	1.20 (1.09–1.31)	< 0.001
Main income earner in the family				
No	Reference		Reference	
Yes	1.28 (1.16-1.42)	<0.001	1.15 (1.03–1.28)	0.010
Shortness of breath				
No	Reference		Reference	
Yes	1.33 (1.21–1.46)	<0.001	1.10 (1.00-1.21)	0.060
Headache				
No	Reference		Reference	
Yes	1.36 (1.24–1.49)	<0.001	1.16 (1.06–1.28)	0.002
Joint pain				
No	Reference		Reference	
Yes	1.33 (1.19–1.48)	<0.001	1.17 (1.06–1.30)	0.003
Loss of ability to speak				
No	Reference		Reference	
Yes	1.39 (1.15–1.70)	0.001	1.19 (0.99–1.42)	0.061

with COVID-19 have higher depression and anxiety scores than men (14–17).

In the multivariate logistics regression results, the common symptoms of shortness of breath, headaches, and joint pain were significant factors related to the HAD group. Furthermore, study subjects being primary income earners were also associated with a 15% increased risk of having HAD status. Healthcare workers also have an increased chance of exposure to COVID-19 (18). This study showed that a decrease in family income due to COVID-19 led to an increase in high-level anxiety/depression status (19). In other studies, asymptomatic patients at the time of testing accounted for 30.8–51.7% (20, 21); this rate differed from our study (5.62%). However, follow-up studies over time show that the proportion of asymptomatic patients was much lower at about 10.7 (22) to 15.6% (23). This difference could be explained by patients being diagnosed at an early stage when they were not showing any symptoms.

Furthermore, a 1-point increase in the medical camp review was associated with a 2% reduction in the likelihood of having HAD status. During the isolation period, patients with COVID-19 shared a small space with limited facilities with other patients with COVID-19. Therefore, it was not surprising that their satisfaction with the medical camp was significantly associated with reduction in HAD status.

There were some limitations to our study. First, although this study was a random selection of patients through an online format, most of the participants were relatively young (mean age was 27.7); thus, it is necessary to investigate with an older participant pool. Second, there is a lack of follow-up in the study design related to depression and anxiety. Follow-up studies would clarify participants' levels of depression and anxiety after being COVID-19-free. Third, this study was conducted based on a self-reported questionnaire, which may involve respondents' bias.

# CONCLUSION

This study indicated that increase in age would increase the likelihood of HAD. The advantage of medical camp has reduced the severity of shortage number of beds in the hospital, low-cost facilities and easy to establish. Moreover, low income and being a primary income earner also increased the risk of having HAD status. Government and policymakers should, thus, offer financial support for lowincome patients with COVID-19. Our study further showed that HAD status was correlated with increase in symptoms of COVID-19. Therefore, psychological consultations in Vietnam's medical camps are necessary to improve patient health conditions.

# DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

### ETHICS STATEMENT

The Ethics Committee approved all procedures of Traditional Medicine Hospital–Ministry of Public Security, Hanoi, Vietnam (No.664/QD-YHCT). The patients/participants provided their written informed consent to participate in this study.

### REFERENCES

- Zhu N, Zhang D, Wang W, Li X, Yang B, Song J. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. (2020) 382:727–33. doi: 10.1056/NEJMoa2001017
- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet.* (2020) 395:497–506. doi: 10.1016/S0140-6736(20)30183-5
- Arons MM, Hatfield KM, Reddy SC, Kimball A, James A, Jacobs JR, et al. Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility. N Engl J Med. (2020) 382:2081–90. doi: 10.1056/NEJM0a2008457
- Harrison AG, Lin T, Wang P. Mechanisms of SARS-CoV-2 transmission and pathogenesis. *Trends Immunol.* (2020) 41:1100–15. doi: 10.1016/j.it.2020.10. 004
- Acter T, Uddin N, Das J, Akhter A, Choudhury TR, Kim S. Evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as coronavirus disease 2019 (COVID-19) pandemic: a global health emergency. *Sci Total Environ.* (2020) 730:138996. doi: 10.1016/j.scitotenv.2020.138996
- Mallah SI, Ghorab OK, Al-Salmi S, Abdellatif OS, Tharmaratnam T, Iskandar MA, et al. COVID-19: breaking down a global health crisis. *Ann Clin Microbiol Antimicrob.* (2021) 20:35. doi: 10.1186/s12941-021-00438-7
- Bac Giang Department of Information and Communication. Report: Summary of COVID-19 Prevention and Control in Bac Giang Province (237/BC-BCD). (2021). Available online at: https://stttt.bacgiang.gov.vn/ documents/21475/11798496/163333534577\_BC-237.pdf/cfb3182d-5a4f-4372-98b5-f1595c9379cd (accessed June 6, 2021).
- Saltzman LY, Hansel TC, Bordnick PS. Loneliness, isolation, and social support factors in post-COVID-19 mental health. *Psychol Trauma*. (2020) 12(Suppl. 1):S55–7. doi: 10.1037/tra0000703
- Vindegaard N, Benros ME. COVID-19 pandemic and mental health consequences: systematic review of the current evidence. *Brain Behav Immun.* (2020) 89:531–42. doi: 10.1016/j.bbi.2020.05.048
- Manea L, Gilbody S, McMillan D. Optimal cut-off score for diagnosing depression with the patient health questionnaire (PHQ-9): a meta-analysis. CMAJ Can Med Assoc J. (2012) 184:E191–6. doi: 10.1503/cmaj.110829
- Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. *Arch Intern Med.* (2006) 166:1092–7. doi: 10.1001/archinte.166.10.1092
- Kong X, Zheng K, Tang M, Kong F, Zhou J, Diao L, et al. Prevalence and factors associated with depression and anxiety of hospitalized patients with COVID-19. *MedRxiv* [Preprint]. (2020). doi: 10.1101/2020.03.24.20043075
- Hu Y, Chen Y, Zheng Y, You C, Tan J, Hu L, et al. Factors related to mental health of inpatients with COVID-19 in Wuhan. China. *Brain Behav Immun.* (2020) 89:587–93. doi: 10.1016/j.bbi.2020.07.016
- Nie XD, Wang Q, Wang MN, Zhao S, Liu L, Zhu YL, et al. Anxiety and depression and its correlates in patients with coronavirus disease 2019 in Wuhan. *Int J Psychiatry Clin Pract.* (2021) 25:109–14. doi: 10.1080/13651501. 2020.1791345
- 15. Guo Q, Zheng Y, Shi J, Wang J, Li G, Li C, et al. Immediate psychological distress in quarantined patients with COVID-19 and its association with

### **AUTHOR CONTRIBUTIONS**

KH, VT, and LV developed the study concept and provided critical revisions. KH, VT, LV, HT, MN, and HN performed the analysis. All authors contributed to draft the manuscript and to the study design and approved the final version of the manuscript for submission.

peripheral inflammation: a mixed-method study. *Brain Behav Immun.* (2020) 88:17–27. doi: 10.1016/j.bbi.2020.05.038

- Htun YM, Thiha K, Aung A, Aung NM, Oo TW, Win PS, et al. Assessment of depressive symptoms in patients with COVID-19 during the second wave of epidemic in Myanmar: a cross-sectional single-center study. *PLoS One.* (2021) 16:e0252189. doi: 10.1371/journal.pone.0252189
- Basheti IA, Mhaidat QN, Mhaidat HN. Prevalence of anxiety and depression during COVID-19 pandemic among healthcare students in Jordan and its effect on their learning process: a national survey. *PLoS One.* (2021) 16:e0249716. doi: 10.1371/journal.pone.0249716
- Cao J, Tu WJ, Cheng W, Yu L, Liu YK, Hu X, et al. Clinical features and short-term outcomes of 102 patients with coronavirus disease 2019 in Wuhan, China. Clin Infect Dis. (2020) 71:748–55. doi: 10.1093/cid/ciaa243
- Tran BX, Nguyen HT, Le HT, Latkin CA, Pham HQ, Vu LG, et al. Impact of COVID-19 on economic well-being and quality of life of the vietnamese during the National social distancing. *Front Psychol.* (2020) 11:565153. doi: 10.3389/fpsyg.2020.565153
- Kimball A, Hatfield KM, Arons M, James A, Taylor J, Spicer K, et al. Asymptomatic and presymptomatic SARS-CoV-2 infections in residents of a long-term care skilled nursing facility – King County, Washington, March 2020. MMWR Morb Mort Wkly Rep. (2020) 69:377–81. doi: 10.15585/mmwr. mm6913e1
- Nishiura H, Kobayashi T, Miyama T, Suzuki A, Jung SM, Hayashi K, et al. Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). Int J Infect Dis. (2020) 94:154–5. doi: 10.1016/j.ijid.2020. 03.020
- Ki M, Task Force for 2019-nCoV. Epidemiologic characteristics of early cases with 2019 novel coronavirus (2019-nCoV) disease in Korea. *Epidemiol Health.* (2020) 42:e2020007. doi: 10.4178/epih.e2020007
- He J, Guo Y, Mao R, Zhang J. Proportion of asymptomatic coronavirus disease 2019: a systematic review and meta-analysis. J Med Virol. (2021) 93:820–30. doi: 10.1002/jmv.26326

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Trang, Huynh, Truong, Nguyen, Hoang, Dao, Van Vu, Hassan, Nguyen and Truong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.